Kevin Kunzmann

The investigational therapy is first being researched for safety and dosage rates before efficacy is considered.

The disparity of fast food swamps significantly affecting pediatric patients with T1D but not those with T2D came as a surprise to researchers.

The therapy, FX1a inhibitor BMS-986177, will advance to phase 2 clinical trials for wider indications.

The therapy regimen is tolerable, safe, and effective for patients attempting to detoxify for an extended opioid agonist treatment.

Next generation sequencing technology is coming on strong in the clinical setting. The FDA would like to help it better reach the market.

The device was able to accurately identify the presence, or lack thereof, of more-than-mild DR at least 87% of the time.

The antipsychotic was approved by the FDA in 2016 on the backing of what researchers now consider unsubstantial clinical evidence.

The Global Burden of Disease study found that US mortality has improved since 1990 — but has been caused by worse health measures.

The long-acting, single-dose nerve block can now be used for popularizing procedures such as total shoulder arthroplasty or rotator cuff repair.

Global studies show the practice is still rare, but growing in countries to have legalized it.

This week on MDNN: Physician report being unaware of how many opioids they prescribe, legalized marijuana cuts down on opioid rates in Medicaid patients, Grindr responds to leak they share users' HIV statuses, and the FDA recalls salmonella-containing kratom.

A new assessment of the association between alcoholism and brain structure is emphasized by current data indicating a major increase of 106.7% in alcohol use disorder in the US population aged 65 years or older.

Researchers observed that prescribing rates were cut by about 6% in at-risk populations from states with legalization laws in place.

The 27-year Navy veteran will assume clinical and administrative roles with the country's largest clinical research-focused hospital.

The Beyond Type 1 Science Advisory Council member explains the warning signs of diabetes.

Lower respiratory infections account for 78.8% of all infectious disease-related deaths, while also reporting the widest absolute mortality inequality among US counties.

A new study found that NAS rates have increased 433% from 2004 to 2014.

The Max SoloStar from Sanofi is capable of carrying 300 units/mL of insulin glargine, and administer 160 units/mL in a single injection.

How the nation’s excessive spending and poor health outcomes drove researchers to seek solutions.

Developers hope the beta-3 agonist can report consistent efficacy and tolerability.

The survey estimates from the National Center for Health Statistics report that more people are vaccinating for flu and testing for HIV.

With the approval, the syringe becomes the first with anti-VEGF agent approved by the FDA for use to treat DR and DME.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

The anti-VEGF marketed as EYLEA has new phase 3 study results in its ongoing trial for NPDR consideration.

The president's remarks in New Hampshire Monday called for judicial action and a law enforcement-centric approach to the opioid epidemic.

The device will offer real-time tracking and alerts for glucose level high and low events, as well as telemedicine capabilities.

New research indicates overweight patients may have worse asthma control outcomes after a year of subcutaneous immunotherapy than their normal weight counterparts.

A joint statement from the Endocrine Society, the ADA, the AACE, and the AADE expressed strong disagreement with the ACP’s new guidelines, which raised goal A1C levels to between 7% and 8% for patients with T2D.

The Vancouver, BC, retrospective cohort study found the HIV-schizophrenia population was mostly white, and mostly males.

Two new women are infected with HIV every minute. How much of a role does dybiosis play in preventive treatment failure?